Trial record 4 of 13 for: "Viral Infectious Disease" | "Amantadine"
TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00867139|
Recruitment Status : Completed
First Posted : March 23, 2009
Results First Posted : June 4, 2013
Last Update Posted : August 15, 2013
Fred Hutchinson Cancer Research Center
Information provided by (Responsible Party):
Michael Boeckh, Fred Hutchinson Cancer Research Center
|Study Design||Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Drug: Zanamivir or Oseltamivir
Other: Open label treatment with TCAD
|Recruitment Details||Patients were recruited from subjects who had a hematopoietic cell transplantation (HCT) within 2 years or combination chemotherapy within 3 months, those with chronic graft-versus-host disease (GVHD) requiring systemic treatment after 2 years post HCT, or with GVHD taking at least 2 immunosuppressive drugs between February - September, 2009|
Study was terminated. Limitations of this study include: small sample size pilot study; inability to enroll the projected number of patients for full analysis before the study was terminated.